Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 269,700 shares, a decline of 29.7% from the December 15th total of 383,700 shares. Currently, 6.8% of the company’s shares are short sold. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is presently 0.3 days.

Allarity Therapeutics Trading Down 5.6 %

ALLR stock opened at $1.01 on Wednesday. The business’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $2.88. Allarity Therapeutics has a twelve month low of $0.90 and a twelve month high of $299.94.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.